24 July 2013
Details
FMC Corporation
has acquired all of the shares of
Epax Nutra Holding lll AS (Norway) and
Epax UK Holding lll AS (United Kingdom) (EPAX),
a leading manufacture of
Omega-3 fatty acid concentrates
that are used in
* nutraceuticals,
* pharmaceuticals and
* food.
EPAX was part of Trygg Pharma Group AS,
an Omega-3 pharmaceutical company.
This acquisition strengthens and expands
FMC's presence in the
high growth nutraceutical market.
FMC's acquisition will include
Epax's two world-scale production facilities in
* Alesund, Norway and
* Seal Sands, UK.
The transaction is valued at approximately $345 million.
WWW.CHEMWINFO.COM BY KHUN PHICHAI
About Omega-3 fatty acids
- The market for supply of Omega-3 fatty acids is
$2.1 billion per year,
- projected to grow 12 percent to 15 percent annually.
- Consumer awareness about Cardiovascular, brain and
numerous health benefits of Omega-3 continues
to drive strong demands, especially for
high purity, highly concentrated products.
FMC,
Pierre Brondeau, President, CEO and Chairman
- Earlier this year, we committed to invest in
our FMC Health and Nutrition platform
by expanding participation in
nutraceuticals and similar high growth markets.
- Today's announcement underscores our commitment
to this strategy to builds on our strengths
in functional ingredients
for the food and pharmaceutical markets.
- It also illustrates our resolve to meet or exceed
FMC's Vision 2015 growth goals
through targeted acquisitions that complement our
technology, business and financial priorities.
WWW.CHEMWINFO.COM BY KHUN PHICHAI
